{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-26-002922","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2026-07-13T22:11:32+00:00","discovered_at":"2026-07-14T10:05:00.232599+00:00","generated_at":"2026-07-14T10:05:47.837752+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IGC Pharma updates investor presentation: Phase 2 CALMA trial >80% enrolled, interim data show agitation reduction","bullets":["Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.","Blinded pooled data (n=107) show LS mean CMAI change of -13.6 at week 2 and -14.9 at week 6 from baseline.","Interim analysis (n=26) showed IGC-AD1 numerically earlier and larger CMAI reduction vs published brexpiprazole data.","Sleep disturbance reduced 71% at week 2 (p=0.012) and 78% at EOT (p=0.02) in interim analysis.","Current market cap ~$30M; presentation outlines potential valuation inflection to $350M-$750M post positive Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002922","json":"https://secwatch.observer/filing/0001185185-26-002922.json","markdown":"https://secwatch.observer/filing/0001185185-26-002922.md","text":"https://secwatch.observer/filing/0001185185-26-002922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/0001185185-26-002922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igc8k071326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T10:05:47.837752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}